JIANGSU GDK(688670)
Search documents
金迪克(688670) - 江苏金迪克生物技术股份有限公司关于召开2025年半年度业绩说明会的公告
2025-08-21 09:16
江苏金迪克生物技术股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码:688670 证券简称:金迪克 公告编号:2025-022 重要内容提示: 会议召开时间:2025 年 9 月 3 日(星期三)13:00-14:00 会议召开地点:上海证券交易所"上证路演中心"网络平台(网址: http://roadshow.sseinfo.com/) 会议召开方式:图文显示(可选)+网络文字互动方式 投资者可于 2025 年 9 月 2 日(星期二)17:00 前将有关问题通过电子邮 件、传真的形式发送至公司邮箱 gdk001@gdkbio.com。公司将在业绩说明会上 对投资者普遍关注的问题进行回答。 江苏金迪克生物技术股份有限公司(以下简称"公司")将于 2025 年 8 月 22 日在《上海证券报》《中国证券报》《证券时报》《证券日报》及上海证券交 易所网站(www.sse.com.cn)披露《江苏金迪克生物技术股份有限公司 2025 年 半年度报告》及《江苏金 ...
金迪克(688670) - 江苏金迪克生物技术股份有限公司2025年半年度募集资金存放与实际使用情况的专项报告
2025-08-21 09:16
证券代码:688670 证券简称:金迪克 公告编号:2025-021 具体情况如下: 单位:万元 | 项目 | 金额 | | --- | --- | | 募集资金总额 | 121,396.00 | | 减:券商承销佣金及保荐费 | 6,349.19 | | 收到募集资金总额 | 115,046.81 | | 减:以募集资金置换预先投入自筹资金的金额 | 14,596.29 | | 减:以募集资金置换预先支付发行费用的金额 | 342.30 | | 减:支付不含税发行费用的金额 | 1,136.90 | | 减:直接投入募集项目的金额 | 88,846.20 | | 减:购买理财产品、定期存款及结构性存款余额 | 5,500.00 | 1 经中国证券监督管理委员会证监许可[2021]1877 号文核准,并经上海证券交 易所同意,本公司由主承销商中信证券股份有限公司于 2021 年 7 月 21 日向社会 公众公开发行普通股(A 股)股票 2,200.00 万股,每股面值 1.00 元,每股发行 价人民币 55.18 元。截至 2021 年 7 月 27 日止,本公司共募集资金 1,213,960,000.00 ...
金迪克(688670) - 江苏金迪克生物技术股份有限公司第二届监事会第十一次会议决议公告
2025-08-21 09:15
证券代码:688670 证券简称:金迪克 公告编号:2025-020 江苏金迪克生物技术股份有限公司 经审议,监事会认为公司 2025 年半年度报告及其摘要的编制和审议程序符 合相关法律法规及《公司章程》等内部规章制度的规定;公司 2025 年半年度报 告的内容和格式符合中国证监会和上海证券交易所的规定,所包含的信息能从 各个方面真实反映出公司 2025 年上半年度的经营管理和财务状况等事项;半年 度报告编制过程中,未发现公司参与半年度报告编制和审议的人员有违反保密 规定的行为;监事会全体成员保证公司 2025 年半年度报告披露的信息真实、准 确、完整,不存在任何虚假记载、误导性陈述或重大遗漏,并对其内容真实性、 准确性和完整性依法承担法律责任。全体监事一致同意通过该报告。 表决结果:同意票 3 票,反对票 0 票,弃权票 0 票。 具体内容详见公司同日在上海证券交易所网站(www.sse.com.cn)披露的 《江苏金迪克生物技术股份有限公司 2025 年半年度报告》和《江苏金迪克生物 技术股份有限公司 2025 年半年度报告摘要》。 第二届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不 ...
金迪克(688670.SH):上半年净亏损3965.31万元
Ge Long Hui A P P· 2025-08-21 09:13
Core Viewpoint - The company, Jindike (688670.SH), reported a revenue increase of 7.18% year-on-year, but still faced a net loss, indicating challenges in profitability despite revenue growth [1] Financial Performance - The company achieved an operating revenue of 3.5242 million yuan, reflecting a year-on-year increase of 7.18% [1] - The net profit attributable to the parent company was -39.6531 million yuan, showing a year-on-year reduction in losses by 2.97% [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was -42.9408 million yuan, with a year-on-year reduction in losses of 8.92% [1] Market Opportunity - The domestic penetration rate of quadrivalent influenza vaccines is significantly lower than that of foreign markets, indicating substantial growth potential [1] - The company aims to capitalize on the steady growth of the influenza vaccine market in China by ensuring product quality and actively pursuing sales transformation [1] - The sales strategy focuses on deepening market penetration, enhancing service to end users, and expanding the incremental market to increase market share in the influenza vaccine sector [1]
金迪克(688670) - 2025 Q2 - 季度财报
2025-08-21 09:10
江苏金迪克生物技术股份有限公司2025 年半年度报告 公司代码:688670 公司简称:金迪克 江苏金迪克生物技术股份有限公司 2025 年半年度报告 1/166 江苏金迪克生物技术股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性,不存在虚假记载、误导性陈述或重大遗漏,并承担个别和连带的法律责任。 二、 重大风险提示 五、 公司负责人余军、主管会计工作负责人黄强及会计机构负责人(会计主管人员)黄强声明: 保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险,敬请查阅本报告第三节 "管理层讨论与分析"中"风险因素"的相关内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及公司未来计划,发展战略等前瞻性描述,不构成对投资者的实质承诺,敬请投 资者注意投资风险。 ...
金迪克:8月20日融资净买入31.61万元,连续3日累计净买入313.45万元
Sou Hu Cai Jing· 2025-08-21 02:29
| 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-20 | 31.61万 | 2246.67万 | 1.08% | | 2025-08-19 | 177.14万 | 2215.06万 | 1.05% | | 2025-08-18 | 104.70万 | 2037.92万 | 1.02% | | 2025-08-15 | 47.58万 | 1933.22万 | 0.98% | | 2025-08-14 | -145.46万 | 1885.64万 | 0.96% | | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-08-20 | 2246.67万 | 31.61万 | 1.43% | | 2025-08-19 | 2215.06万 | 177.14万 | 8.69% | | 2025-08-18 | 2037.92万 | 104.70万 | 5.42% | | 2025-08-15 | 1933.22万 | 47.58万 | 2. ...
被大疆正面硬刚的Insta360,拿什么笑下去?
Hu Xiu· 2025-08-15 02:46
Group 1 - DJI launched the Osmo 360, entering the 360-degree camera market dominated by Insta360 [1][2] - Osmo 360 sold out within an hour of its release, indicating strong demand and competition in the market [2][4] - The introduction of Osmo 360 has prompted Insta360 to lower the price of its latest model, Insta360 X5, by 500 yuan, narrowing the price gap to under 300 yuan [2][4] Group 2 - Insta360 has successfully leveraged social media to create viral content, enhancing brand visibility and user engagement [10][12] - The rise of short video platforms has significantly increased the demand for unique and portable imaging devices like Insta360 [13][14] - The outdoor activity market has expanded, driving the demand for action cameras, with the outdoor equipment market growing from 67.5 billion yuan in 2019 to 87.2 billion yuan in 2023 [17][22] Group 3 - Insta360's market share reached 67% in the global 360-degree camera market as of 2023, showcasing its strong position [25] - The company has focused on making its products user-friendly, allowing consumers to easily create and share content [26][27] - Insta360's marketing strategy relies on user-generated content and social media engagement rather than traditional advertising [28][45] Group 4 - Insta360's revenue for 2024 is projected at 5.574 billion yuan, with a compound annual growth rate of 65.25% over the past three years [47] - The global 360-degree camera market is expected to grow from 13.814 billion dollars in 2023 to 81.335 billion dollars by 2030, with a compound annual growth rate of 28.8% [47] - The company plans to invest in R&D and expand its product offerings to maintain its competitive edge [49][50] Group 5 - Insta360 faces ongoing legal challenges from GoPro regarding patent infringements, which could impact its operations in the U.S. market [51][52] - The company is expanding its global presence, particularly in North America, where it has seen significant website traffic [50] - The focus on enhancing user experience through offline retail and workshops has proven effective in converting interest into sales [43][44]
生物制品上市公司董秘PK:辽宁成大邱闯成为业内唯一博士董秘 今年5月刚刚上任
Xin Lang Zheng Quan· 2025-08-01 05:24
Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 secretaries earned over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for secretaries in the A-share biopharmaceutical sector is 1.01 million yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] Age and Education Distribution - The age distribution of secretaries shows that those aged 40-50 constitute 61%, while those over 50 account for 15%, and those aged 30-40 make up 18% [1] - In terms of education, 52% of secretaries hold a bachelor's degree, while 44% have a master's degree, and only 2% possess a doctoral degree [3] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [7] - The top five companies with the highest number of investor meetings are: Bohui Innovation (1,500 meetings), Jindike (777 meetings), Nearshore Protein (681 meetings), Sailun Biotech (549 meetings), and Kanghua Biotech (504 meetings) [9]
生物制品上市公司董秘PK:康乐卫士任恩奇为行业最年轻董秘 任职已满1年年薪38.32万元
Xin Lang Zheng Quan· 2025-08-01 05:20
Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for company secretaries in the biopharmaceutical sector is 1.01 million yuan, with the distribution of salaries as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] - The top five highest-paid company secretaries have salaries of 3.2565 million yuan, 2.5345 million yuan, 2.2809 million yuan, 1.9265 million yuan, and 1.89 million yuan, with their tenure at the companies ranging from less than one year to 15 years [7] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 61%, while those over 50 account for 15%, and those under 30 make up 6% [1][3] - The educational background indicates that 52% hold a bachelor's degree, 44% have a master's degree, and only 2% possess a doctoral degree, with the latter represented by just one individual [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually, while only 2% have more than 1,000 meetings [9] - The five companies with the highest number of investor meetings are reported to have 1,500, 777, 681, 549, and 504 meetings, respectively [9]
李想:理想i8发布会大概率要「致敬小米」!特别感谢雷总的「定心丸」;罗马仕中层:五个老板全跑马来西亚了;传阿里副总裁叶军将离职
雷峰网· 2025-07-14 00:35
Group 1 - NIO's Vice President denies layoffs, stating it is a "team optimization adjustment" to match market changes, with CEO Li Bin expressing reluctance but understanding of the situation [4][5][6] - NIO's new model, the L90, has a starting price of 27.99 million yuan for purchase and 19.39 million yuan for battery rental, with a focus on creating user value [5][6] - NIO's recent capital increase of 120 billion yuan for its sales service company and 80 billion yuan for its technology company, supported by state-owned enterprises, aims to bolster its strategic upgrades [13][14] Group 2 - Reports suggest Alibaba's Vice President and former DingTalk CEO Ye Jun is set to leave the company, with no official response yet [8] - Li Xiang, CEO of Li Auto, hints that the upcoming i8 launch event will likely pay tribute to Xiaomi, indicating a significant marketing strategy [9] - The company Romashi faces severe financial issues, with reports of its core management fleeing to Malaysia and a monthly sales figure of approximately 200 million yuan, leading to a cash flow crisis [12][13] Group 3 - Huawei announces a timeline for L3 and L4 autonomous driving, with L3 expected to commercialize in 2025 and L4 in 2026, aiming to lead the market ahead of competitors like Tesla [16][17] - Intel announces significant layoffs, with over 500 engineers affected, as part of a restructuring effort to streamline operations [34] - Xiaomi's market share in China's smartphone market reaches 16.63%, with a year-on-year growth of 7.39%, reflecting its strong competitive position [14] Group 4 - JD.com launches aggressive promotions in the food delivery sector, with significant discounts and offers to attract customers, indicating a competitive landscape [22] - Volkswagen's CEO praises BYD as a respectable competitor, highlighting the importance of competition in driving industry innovation [32] - Xpeng Motors commits to a 60-day payment term for suppliers, aiming to stabilize relationships and improve industry practices [31]